




# IV CIBERONC GENERAL MEETING



#IVCGM @CIBERONC

February 14<sup>th</sup> 2020

Escuela Nacional de Sanidad

Salón de Actos Pittaluga

(Calle Sinesio Delgado, 10, 28029 Madrid)



**ciberonc**  
Centro de Investigación Biomédica en Red  
Cáncer



**isc**  
Instituto  
de Salud  
Carlos III



Unión Europea

FONDO EUROPEO DE  
DESARROLLO REGIONAL  
*Una manera de hacer Europa*  
FONDO SOCIAL EUROPEO  
*El FSE invierte en tu futuro*

# IV CIBERONC GENERAL MEETING

**9:00** Registrations

**9:30** Welcome

Raquel Yotti. *Director of ISCIII*

Margarita Blázquez. *Deputy Director of Networks and Cooperative Research Centers*

Joaquín Arribas. *Scientific Director of CIBERONC*

## **10:00** Special session: Genomics analysis in cancer research

Chair: Joaquín Arribas. *Scientific Director of CIBERONC*

Invited speaker: **Núria López-Bigas**. *IRB.*

*Computational analysis of cancer genomes*

**11:00** Coffee Break (aula 9/10)

## **Best CIBERONC publications**

Chair: Anna Bigas. *IMIM*

### **11:40** Gastro-Intestinal Tumors Program

*Urothelial organoids originating from Cd49fhigh mouse stem cells display Notch-dependent differentiation capacity.* **Francisco X. Real**. *CNIO*

### **12:20** Breast Cancer Program


*High numbers of circulating CD57+ NK cells associate with resistance to her2-specific therapeutic antibodies in HER2+ primary breast cancer.* **Joan Albanell**. *IMIM*

### **13:00** Respiratory Tract Tumors Program

*YES1 Drives Lung Cancer Growth and Progression and Predicts Sensitivity to Dasatinib.* **Alfonso Calvo**. *CIMA*

**13:40** Lunch (aula 9/10)

**14:30** Official photo of the meeting (entrance of the ENS)



# IV CIBERONC GENERAL MEETING

## Best CIBERONC publications

Chair: Dolors Colomer. IDIBAPS

### 14:40 Hematological Tumors Program

*PD-1/PD-L1 immune checkpoint and p53 loss facilitate tumor progression in activated B-cell diffuse large B-cell lymphomas. Sergio Roa. CIMA*

### 15:20 Low Prevalence Tumors Program

*Preclinical Efficacy of Endoglin-Targeting Antibody-Drug Conjugates for the Treatment of Ewing Sarcoma. Teresa Amaral. IBIS*

### 16:00 Mechanisms of Tumor Progression Program

*Inhibition of a G9a/DNMT network triggers immune-mediated bladder cancer regression. Jesús Paramio. CIEMAT*

### 16:40 Coffee Break (aula 9/10)

## Awards

Chair: Amparo Cano. IIB-UAM

### 17:00 Best CIBERONC Young Leader Researcher

### 17:30 Best CIBERONC Female Researcher

### 18:00 Most Collaborative CIBERONC article

*Ultra-selection of metastatic colorectal cancer patients using Next Generation Sequencing to improve clinical efficacy of anti-EGFR therapy. Joana Vidal. IMIM*

## TRAINING & MOBILITY PROGRAM

### MOBILITY



Jan - Feb  
Apr - May

### TRAINING



Feb - Mar  
May - Jun

### INITIATION



Mar - Apr

### PROMOTION



Jun - Ago

20<sup>th</sup>  
Opening  
15<sup>th</sup>  
Deadline  
25<sup>th</sup>  
Resolution

# 2019 in figures



**11 Meetings**

**1 General Meeting**

**1 Young Researchers Meeting**

**2 Workshops**

**7 Program Meetings**



**769 Scientific publications**



[www.ciberonc.es](http://www.ciberonc.es)



**6 Internal projects funded**



**728 Members**

**73 Employees**



**60 Training and mobility grants**